SELLAS Life Sciences Group focuses exclusively on clinical-stage cancer therapies, including licensed assets SLS009 and GPS. Despite ongoing net losses and negative operating cash flow reflecting its pre-commercial status, the company maintains a strong liquidity position with $71.8 million cash at end-2025 plus additional warrant exercise proceeds post-year-end. Future growth hinges on clinical trial success, regulatory approvals, partnerships, and further financing to sustain operations amid high development costs.